Anti-Rheumatic Drugs - Argentina

Argentina

The Anti-Rheumatic Drugs market in Argentina is expected to witness a significant growth in revenue, reaching a projected value of US$100.20m by the year 2024.
This growth is anticipated to continue at an annual growth rate (CAGR 2024-2029) of 0.32%, leading to a market volume of US$101.80m by the year 2029.
It is worth noting that in a global comparison, United States is expected to generate the highest revenue in this market, with an estimated value of US$34,700.00m in 2024.
In Argentina, the market for Anti-Rheumatic Drugs is experiencing a surge in demand due to an aging population and increasing prevalence of rheumatic diseases.

Key regions: Germany, United States, India, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Rheumatic Drugs market in Argentina has been showing an upward trend in recent years.

Customer preferences: Patients suffering from rheumatoid arthritis, osteoarthritis, and other related diseases in Argentina prefer to use anti-rheumatic drugs for pain management and to improve their quality of life. The increasing awareness and acceptance of these drugs as a treatment option have contributed to the growth of the market.

Trends in the market: The Anti-Rheumatic Drugs market in Argentina has been experiencing a significant increase in demand due to the aging population and a rise in the prevalence of rheumatic diseases. The market has also been driven by the introduction of new drugs and therapies, including biologics and biosimilars. These drugs have shown promising results in treating rheumatoid arthritis and other related diseases, leading to an increase in their adoption.

Local special circumstances: One of the unique aspects of the Anti-Rheumatic Drugs market in Argentina is the availability of biosimilars. Biosimilars are drugs that are similar to biologics but are less expensive. The availability of biosimilars has made it easier for patients to access treatment and has contributed to the growth of the market.

Underlying macroeconomic factors: The growth of the Anti-Rheumatic Drugs market in Argentina can be attributed to several macroeconomic factors. The aging population and the rise in the prevalence of rheumatic diseases have increased the demand for these drugs. The government's efforts to improve healthcare infrastructure and the availability of affordable drugs have also contributed to the growth of the market. Additionally, the increasing acceptance of biosimilars has made it easier for patients to access treatment and has contributed to the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.